Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'

Raphaël Maréchal, Jean–Baptiste Bachet, John R Mackey, Cécile Dalban, Pieter Demetter, Kathryn Graham, Anne Couvelard, Magali Svrcek, Armelle Bardier–Dupas, Pascal Hammel, Alain Sauvanet, Christophe Louvet, François Paye, Philippe Rougier, Christophe Penna, Thierry André, Charles Dumontet, Carol E Cass, Lars Petter Jordheim, Eva–Laure Matera, Jean Closset, Isabelle Salmon, Jacques Devière, Jean–François Emile, Jean–Luc Van Laethem, None, Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma Gastroenterology. ,vol. 143, pp. 664- 674.e6 ,(2012) , 10.1053/J.GASTRO.2012.06.006

J.-B. Bachet, E. Mitry, A. Lièvre, C. Lepère, J.-N. Vaillant, G. Declety, H. Parlier, J.-F. Emile, C. Julié, P. Rougier, Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients Gastroenterologie Clinique Et Biologique. ,vol. 33, pp. 1036- 1044 ,(2009) , 10.1016/J.GCB.2009.03.017

Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, Pascal Artru, Mélanie Gauthier, Thierry Lecomte, Thomas Aparicio, Anne Thirot-Bidault, Céline Lobry, Amani Asnacios, Sophie Manet-Lacombe, Francine Fein, Olivier Dubreuil, Bruno Landi, Aziz Zaanan, Franck Bonnetain, Julien Taïeb, Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). European Journal of Cancer. ,vol. 50, pp. 3116- 3124 ,(2014) , 10.1016/J.EJCA.2014.09.015

D D Von Hoff, There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clinical Cancer Research. ,vol. 4, pp. 1079- 1086 ,(1998)

Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel Laheru, Nathan Bahary, Ramesh K Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, Jose Iglesias, Markus F Renschler, None, Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine The New England Journal of Medicine. ,vol. 369, pp. 1691- 1703 ,(2013) , 10.1056/NEJMOA1304369

Alix Portal, Simon Pernot, David Tougeron, Claire Arbaud, Anne Thirot Bidault, Christelle de la Fouchardière, Pascal Hammel, Thierry Lecomte, Johann Dréanic, Romain Coriat, Jean-Baptiste Bachet, Olivier Dubreuil, Lysiane Marthey, Laetitia Dahan, Belinda Tchoundjeu, Christophe Locher, Céline Lepère, Franck Bonnetain, Julien Taieb, Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort British Journal of Cancer. ,vol. 113, pp. 989- 995 ,(2015) , 10.1038/BJC.2015.328

C. Vivaldi, C. Caparello, G. Pasquini, G. Musettini, S. Catanese, M. Lencioni, A. Falcone, E. Vasile, P-180Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study Annals of Oncology. ,vol. 26, ,(2015) , 10.1093/ANNONC/MDV233.180

C. Vivaldi, E. Vasile, L. Fornaro, C. Caparello, G. Musettini, G. Pasquini, M. Lencioni, S. Ricci, A. Falcone, 2362 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients European Journal of Cancer. ,vol. 51, ,(2015) , 10.1016/S0959-8049(16)31278-3